P230 Development of a Japanese version of the IBD Self-Efficacy Scale and evaluation of its current status in Japan

Abstract

Background In chronic diseases like inflammatory bowel disease (IBD), self-efficacy is one of important health outcomes. The IBD-Self-Efficacy Scale (IBD-SES) is an outcome measure used in research settings. In this study, we aimed to develop a Japanese version of IBD-SES and investigate the self-efficacy of IBD patients in Japan. Methods We conducted a questionnaire survey with IBD patients from two different sources: outpatients of a specialized IBD clinic and respondents recruited online. The original 29-item IBD-SES, with scores from 1 (not at all) to 10 (totally) in each item, and higher scores indicating greater self-management efficacy, was translated into Japanese with permission of the original author and was used for the surveys after confirming its linguistic equivalence with the original version. The reliability of the scale was assessed by calculating the Cronbach’s alpha coefficient for internal consistency, and the validity was assessed by disease activity (remission vs. active period) for known-group validity. Items of IBD-SES score comparison between the outpatient clinic group and online group were performed by t-test. Results A total of 919 valid responses were obtained, 482 patients (ulcerative colitis (UC): 184, Crohn’s disease (CD): 298) from the specialized IBD clinic and 437 (UC: 255, CD: 182) online. The mean score per item for each subscale [Stress & Emotion Management], [Outpatient care & medication management], [Symptom & disease management] and [Maintenance of remission] was 4.7, 7.3, 4.9, and 4.9, respectively. Internal consistency was confirmed on each subscale (Cronbach’s α: 0.85–0.94). Comparing remission and active periods, significant differences were observed in three subscales: [Stress & Emotion Management (p < 0.001)], [Symptom & disease management (p < 0.001)] and [Maintenance of remission (p < 0.001)], and the known group validity was mostly confirmed. Conclusion This study demonstrates the reliability and validity of the Japanese version of the IBD-SES and reveals the current status of self-efficacy of the self-management of IBD patients in Japan. Compared to previous studies using IBD-SES in the USA or Canada, scores observed with Japanese IBD patients are lower. It might reflect a cultural difference.

Daily life difficulties among patients with ulcerative colitis in Japan and the United Kingdom: A comparative study

“…First, fatigue is highly correlated with a decline of vitality or vigor. [ 14 ] A review by D’Silva et al [ 15 ] reported that the prevalence of fatigue in patients with UC was 36% and is considered common. Seventy-two percent of patients with active disease experience fatigue.…”

“…[ 7 ] The survey in Japan was conducted at the Kinshukai Infusion Clinic from July to September 2019. [ 14 ] Sociodemographic and clinical characteristics of participants in the UK were reported in a previous study. [ 7 ]…”

“…Patients were excluded if they were intolerant of 5-ASA; had a history of surgery for UC; were unable to complete the questionnaire or understand English; had any serious complications; or were participating in other clinical studies at the time of study entry. In keeping with the UK study, among Japanese patients reported in our previous study, [ 14 ] patients attending Kinshukai Infusion Clinic who met the following eligibility criteria were included in the present study: diagnosed with UC, aged 20 years or older, prescribed 5-ASA, without a history of surgery for UC, and without serious complications. Both study facilities were equipped to provide specialized care for patients with IBD.…”